The University of Southampton
University of Southampton Institutional Repository

The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being

The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being
The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being
AIM: As many overweight people with T1DM are insulin resistant, adjuvant therapy with insulin sensitising agents, such as metformin, may be beneficial. This study evaluated the effect of adjuvant metformin in T1DM on insulin sensitivity, diabetic control, body composition, quality of life (QOL) and treatment satisfaction. MATERIALS AND METHODS: A 3-month prospective open-labelled pilot study of 16 patients aged 18-40 with T1DM and body mass index (BMI) >25 kg/m(2) was performed. The patients received 500-850 mg metformin twice daily. Insulin sensitivity, assessed by a frequently sampled intravenous glucose tolerance test [n=5], body composition, HbA(1c) and quality of life (QOL) were measured before and after treatment. A retrospective review of 30 patients with T1DM treated with metformin for at least 4 months was also performed. BMI, HbA(1c) and insulin requirements during metformin treatment was compared to pre-metformin data, and to patients treated with insulin only. RESULTS: In the pilot study, insulin sensitivity increased significantly from 0.86 +/- 0.33 x 10(-4)/min/(microU/ml) to 1.17 +/- 0.48 x 10(-4)/min/(microU/ml) after 3 months adjuvant therapy (p = 0.043). This was associated with a decreased insulin requirement and mean daily blood glucose. There were no significant changes in HbA(1c) or body composition. QOL significantly improved (p < 0.002). The retrospective review revealed an initial reduction in HbA(1c) (0.8 +/- 1.4%, p = 0.001). This effect diminished with prolonged treatment. BMI decreased in patients remaining on metformin for a 2-year period (0.5 +/- 0.5kg/m(2), p = 0.042). CONCLUSION: Adjuvant metformin can improve QOL, insulin sensitivity and glycaemic control in overweight adults with T1DM
drug therapy, diabetes, research, blood, insulin sensitivity, overweight, metformin, pilot projects, insulin, adult, quality of life, glucose tolerance, humans, glucose, drug effects, hypoglycemic agents, type 1, adolescent, review, letter, body composition, combination, glucose tolerance test, diabetes mellitus, therapy, methods, blood glucose, aged, therapeutic use, body mass index, insulin resistance
1462-8902
143-145
Moon, R.J.
954fb3ed-9934-4649-886d-f65944985a6b
Bascombe, L.A.
3aabf992-ebbc-46fb-b93a-ba7fa9abb499
Holt, R.I.
d54202e1-fcf6-4a17-a320-9f32d7024393
Moon, R.J.
954fb3ed-9934-4649-886d-f65944985a6b
Bascombe, L.A.
3aabf992-ebbc-46fb-b93a-ba7fa9abb499
Holt, R.I.
d54202e1-fcf6-4a17-a320-9f32d7024393

Moon, R.J., Bascombe, L.A. and Holt, R.I. (2007) The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes, Obesity and Metabolism, 9 (1), 143-145.

Record type: Article

Abstract

AIM: As many overweight people with T1DM are insulin resistant, adjuvant therapy with insulin sensitising agents, such as metformin, may be beneficial. This study evaluated the effect of adjuvant metformin in T1DM on insulin sensitivity, diabetic control, body composition, quality of life (QOL) and treatment satisfaction. MATERIALS AND METHODS: A 3-month prospective open-labelled pilot study of 16 patients aged 18-40 with T1DM and body mass index (BMI) >25 kg/m(2) was performed. The patients received 500-850 mg metformin twice daily. Insulin sensitivity, assessed by a frequently sampled intravenous glucose tolerance test [n=5], body composition, HbA(1c) and quality of life (QOL) were measured before and after treatment. A retrospective review of 30 patients with T1DM treated with metformin for at least 4 months was also performed. BMI, HbA(1c) and insulin requirements during metformin treatment was compared to pre-metformin data, and to patients treated with insulin only. RESULTS: In the pilot study, insulin sensitivity increased significantly from 0.86 +/- 0.33 x 10(-4)/min/(microU/ml) to 1.17 +/- 0.48 x 10(-4)/min/(microU/ml) after 3 months adjuvant therapy (p = 0.043). This was associated with a decreased insulin requirement and mean daily blood glucose. There were no significant changes in HbA(1c) or body composition. QOL significantly improved (p < 0.002). The retrospective review revealed an initial reduction in HbA(1c) (0.8 +/- 1.4%, p = 0.001). This effect diminished with prolonged treatment. BMI decreased in patients remaining on metformin for a 2-year period (0.5 +/- 0.5kg/m(2), p = 0.042). CONCLUSION: Adjuvant metformin can improve QOL, insulin sensitivity and glycaemic control in overweight adults with T1DM

This record has no associated files available for download.

More information

Published date: 2007
Keywords: drug therapy, diabetes, research, blood, insulin sensitivity, overweight, metformin, pilot projects, insulin, adult, quality of life, glucose tolerance, humans, glucose, drug effects, hypoglycemic agents, type 1, adolescent, review, letter, body composition, combination, glucose tolerance test, diabetes mellitus, therapy, methods, blood glucose, aged, therapeutic use, body mass index, insulin resistance

Identifiers

Local EPrints ID: 61384
URI: http://eprints.soton.ac.uk/id/eprint/61384
ISSN: 1462-8902
PURE UUID: 6f8d96f1-b685-4241-8168-d515d5205323
ORCID for R.I. Holt: ORCID iD orcid.org/0000-0001-8911-6744

Catalogue record

Date deposited: 10 Sep 2008
Last modified: 23 Jul 2022 01:48

Export record

Contributors

Author: R.J. Moon
Author: L.A. Bascombe
Author: R.I. Holt ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×